Format

Send to

Choose Destination
ACS Chem Biol. 2006 Jun 20;1(5):279-84.

Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive.

Author information

1
Department of Medicine and Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA.

Abstract

Two recent papers attempt to solve both the tumor selectivity and the in vivo tumor accumulation profiles seen with some Hsp90 inhibitors. They spotlight the higher affinity of ansamycins' hydroquinone over the quinone form for Hsp90 and further discuss its possible contribution to ansamycins' tumor selectivity.

PMID:
17163756
DOI:
10.1021/cb600224w
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center